ASCIMINIB 40 mg (Kyzific) x 60 Tablets

Uses of ASCIMINIB 40 mg

• Treats chronic myeloid leukemia (CML) in adults.
• Used in Philadelphia chromosome-positive CML.
• Used in patients who are resistant or intolerant to other TKIs (like imatinib, dasatinib, nilotinib).
• Helps control disease in advanced or chronic phases.

Benefits of ASCIMINIB 40 mg

• Targets cancer cells more precisely than older TKIs.
• Works in cases where other treatments fail.
• Helps reduce leukemia cell levels.
• Oral therapy with convenient dosing.
• May improve long-term disease control.

How does it work?

Asciminib is a targeted cancer medicine that works as a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket). It blocks the BCR-ABL1 protein that drives chronic myeloid leukemia, stopping the abnormal signaling that causes uncontrolled white blood cell growth.

Precautions

• Take exactly as prescribed.
• Do not change dose without doctor advice.
• Take on an empty stomach or as directed.
• Monitor blood counts regularly.
• Inform your doctor about heart, liver, or pancreas problems.
• Tell your doctor about all medicines you are taking.
• Report severe fatigue, abdominal pain, or unusual symptoms immediately.

Side Effects

• Fatigue
• Nausea
• Headache
• Low blood cell counts

Asciminib 40mg (Kyzific) Tablets at competitive wholesale prices from our trusted generic pharmacy

We supply authentic Asciminib 40 mg (Kyzific) Tablets, a trusted therapy used for the effective management of chronic myeloid leukemia (CML).

As a global pharmaceutical wholesaler with extensive export expertise, we deliver high‑quality generic oncology medicines to patients, hospitals, physicians, clinics, and healthcare centers in countries including Colombia, Peru, the Philippines, Venezuela, Panama, Ecuador, Namibia, South Africa, Zimbabwe, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Palestine, Qatar, Saudi Arabia, the United Arab Emirates, China, Canada, Brazil, Mexico, Russia, Thailand, Malaysia, Singapore, Vietnam, South Korea, Taiwan, Indonesia, the United States, and more.